Replimune Groupの空売り状況は、投資家がReplimune Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Replimune Group (NASDAQ:REPL) 株価情報, 空売り情報

Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group Inc

REPLENISH NUTRIENTS HLDG by REPLENISH NUTRIENTS HLDG CORP.

Replenish Nutrients Holding Corp

REPLICEL LIFE SCIENCE ORD by RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc

Repligen Corp

Reply SpA

WIIM

LSCC

Lattice Semiconductor shares are trading higher following mixed Q4 results.

News

Tech

General

DGHI

Digihost Forms Wholly-Owned Subsidiary, US Data Centers To Develop High-Performance Computing And AI-Tier Data Centers

AMKR

Amkor Technology shares are trading lower after the company missed Q4 revenue estimates.

Citigroup analyst Tyler Radke maintains Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and raises the price target from $14 to $22.

Price Target

Analyst Ratings

SMWB

Citigroup Maintains Buy on Similarweb, Raises Price Target to $22

Keybanc analyst Philip Gibbs upgrades Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) from Sector Weight to Overweight and announces $155 price target.

Upgrades

STLD

Keybanc Upgrades Steel Dynamics to Overweight, Announces $155 Price Target

Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to US$15,000,000 of the Company's common shares (the "Shares") to the Investor at any time during the 36-months following the date of the SEPA.
The Investor's obligation to purchase Shares is subject to a number of conditions, including that the Company file a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale of the Shares issuable thereunder, and that the registration statement is declared effective by the SEC.
The total number of Shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding Shares as of the date of the SEPA unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to the Company under the SEPA. The issuance of Shares under the SEPA is subject to further limitations, including that the Shares beneficially owned by the Investor and its affiliates at any one time will not exceed 4.99% of the then-outstanding Shares.
Shares issued and sold to the Investor under the SEPA will be priced at 97% of the Market Price (as defined in the SEPA) of the Shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the Share issuances.

MDCX

Medicus Pharma Secures $15M Equity Purchase Agreement With Yorkville Advisors

OESX

Orion Energy Sees FY25 Revenue Outlook Of Approximately 10% Growth, Expects Second Half Revenue To Be More Weighted To Q4

NCNO

nCino Acquires Sandbox Banking For $52.5M In Cash With Additional Earn-Out Up To $10M Based On Metrics

Citigroup analyst Tyler Radke maintains Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) with a Buy and raises the price target from $143 to $175.

SHOP

Citigroup Maintains Buy on Shopify, Raises Price Target to $175

2024 Production Results
<ul>
<li>Record quarterly copper production of 12,883 tonnes contributed to consolidated copper production for 2024 of 40,600 tonnes in concentrate.
<ul>
<li>The Caraíba Operations delivered 8,566 tonnes during the fourth quarter and 35,444 tonnes of copper in concentrate for the year, meeting revised 2024 production guidance.</li>
<li>Steady progress on increasing throughput volumes through year-end at the Tucumã Operation resulted in production of 4,317 tonnes during the fourth quarter and 5,156 tonnes of copper in concentrate for the year, below revised 2024 guidance.</li>
</ul>
</li>
<li>Gold production of 57,210 ounces at the Xavantina Operations was at the midpoint of original guidance and slightly below increased 2024 guidance.</li>
</ul>

Ero Copper Reports Record 2024 Copper Output Of 40,600 Tonnes—Projects Up To 85,000 Tonnes In 2025 With Major Growth Ahead

The Tetra-6 mission is a follow-on contract to the USSF/Air Force Research Laboratory (AFRL) Tetra-5 mission, for which Redwire is delivering two Mako spacecraft.

Contracts

Redwire Secures Follow-on Contract To Deliver Third Mako Spacecraft For US Space Force

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $450 to $459.

VRTX

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $459

BHVN

Biohaven Announces FDA Acceptance And Priority Review Of Its New Drug Application For Troriluzole In Treatment Of Spinocerebellar Ataxia

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and lowers the price target from $230 to $210.

SPSC

Needham Maintains Buy on SPS Commerce, Lowers Price Target to $210

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $19.584 million which missed the analyst consensus estimate of $27.266 million by 28.17 percent. This is a 24.59 percent decrease over sales of $25.971 million the same period last year.

Earnings

Earnings Misses

Orion Energy Sys Q3 2025 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $19.584M Miss $27.266M Estimate

Needham analyst Charles Shi reiterates Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and maintains $34 price target.

Reiteration

Needham Reiterates Buy on Amkor Tech, Maintains $34 Price Target

Citigroup analyst Tyler Radke maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Neutral and raises the price target from $39 to $48.

KVYO

Citigroup Maintains Neutral on Klaviyo, Raises Price Target to $48

Citigroup analyst Drew Foster maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $750 to $900.

HUBS

Citigroup Maintains Buy on HubSpot, Raises Price Target to $900

The OASIS+ vehicle has an estimated total spend of $60 billion over a maximum of 10 years.

Comments

Replimune Group

空売り

Replimune Group (NASDAQ:REPL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル